Guevara Gonzalo, González Jaime A, Lopera Diego E, González Manuel, Saavedra José D, Lobaton José Fernando, Duque Jorge Enrique
Instituto Colombiano de Genética y Oncologia Molecular E-mail:
Oncologos de Occidente, Armenia, Colombia. E-mail:
Colomb Med (Cali). 2012 Dec 30;43(4):267-72. eCollection 2012 Oct.
To evaluate the hematological, cytogenetic, and molecular responses in Colombian patients with CML chronic myeloid leukemia (CML) treated with imatinib.
Two groups of patients, one with the novo diagnostic and another in state of complete cytogenetic remission were followed for 12 months with quantitative PCR evaluations every three months and with chromosomal analysis every 6 months.
The group with the novo diagnosis showed 50% of complete cytogenetic remission at 12 months while the other 50% were considered to have primary resistance. Respect the molecular analysis, 10.5% of the patients reached undetectable BCR-ABL transcripts at 12 months. In the complete cytogenetic remission group, 10.6% lost the state of complete cytogenetic remission at 12 months, 50% reached undetectable BCR-ABL transcripts but 10% showed levels higher than 10%, which in our standardization was equal to no molecular response.
Despite having received the conventional dosages of 400 mg/day of imatinib, the cytogenetic and molecular responses obtained in our group of Colombian patients with CML, were lower than those in other international studies.
评估接受伊马替尼治疗的哥伦比亚慢性髓性白血病（CML）患者的血液学、细胞遗传学和分子反应。
两组患者，一组为初诊患者，另一组为处于完全细胞遗传学缓解状态的患者，随访12个月，每三个月进行一次定量PCR评估，每6个月进行一次染色体分析。
初诊组在12个月时显示50%达到完全细胞遗传学缓解，而另外50%被认为存在原发性耐药。在分子分析方面，10.5%的患者在12个月时达到检测不到BCR-ABL转录本的水平。在完全细胞遗传学缓解组中，10.6%的患者在12个月时失去完全细胞遗传学缓解状态，50%达到检测不到BCR-ABL转录本的水平，但10%的患者显示水平高于10%，按照我们的标准这等同于无分子反应。
尽管接受了伊马替尼400毫克/天的常规剂量，但我们这组哥伦比亚CML患者获得的细胞遗传学和分子反应低于其他国际研究中的反应。
